Tin tức & Cập nhật

Obesity diagnosis should be based beyond BMI alone and include assessment of excess adiposity, organ dysfunction, daily activity limitations, and obesity-related diseases. A treat-to-target approach should be adopted to achieve disease-modifying effects and reduce obesity-related complications, according to Dr Samantha Hocking of the University of Sydney, Australia, who spoke at the 8^th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.

The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.